Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future

Pharmacotherapy. 2018 Feb;38(2):164-171. doi: 10.1002/phar.2074. Epub 2018 Jan 10.

Authors

Evan M Sisson¹, Lauren Pamulapati¹, John D Bucheit¹, Michael S Kelly², Dave L Dixon¹

Affiliations

¹ Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia.
² Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, California.

PMID: 29266309
DOI: 10.1002/phar.2074

No abstract available

Keywords: PCSK9 inhibitors; cardiovascular disease; dyslipidemia; ezetimibe; guidelines; statins.

Publication types

Review

MeSH terms

Anticholesteremic Agents / therapeutic use*
Cardiovascular Diseases / blood
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / drug therapy*
Disease Management*
Dyslipidemias / blood
Dyslipidemias / diagnosis
Dyslipidemias / drug therapy*
Forecasting
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
PCSK9 Inhibitors
Proprotein Convertase 9 / blood
Risk Factors

Substances

Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9